Altamira Therapeutics Ltd. (CYTOF) Executive Compensation
Altamira Therapeutics Ltd. (CYTOF) is a publicly traded company on the OTC, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: CYTOF
CIK: 1601936
Exchange: OTC
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 12/31
State: D0
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
BDO AG
Auditor SinceSince 12/31/2023 12:00:00 AM
Lead Engagement PartnerChristoph Tschumi
Audit LocationZurich, Switzerland
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 15-12G | 2026-02-27 | — | FORM 15-12B | 0001213900-26-021580 | View SEC Doc Filr Page |
| 6-K | 2025-08-29 | 2025-06-30 | REPORT OF FOREIGN PRIVATE ISSUER | 0001213900-25-082071 | View SEC Doc Filr Page |
| 25-NSE | 2025-06-17 | — | 25-NSE Filing | 0001354457-25-000544 | View SEC Doc Filr Page |
| 6-K | 2025-06-11 | 2025-06-11 | FORM 6-K | 0001213900-25-053451 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2025-05-15 | — | SCHEDULE 13G/A Filing | 0001172661-25-002248 | View SEC Doc Filr Page |
| 6-K | 2025-05-09 | 2025-05-09 | REPORT OF FOREIGN PRIVATE ISSUER | 0001213900-25-041560 | View SEC Doc Filr Page |
| SCHEDULE 13D/A | 2025-05-06 | — | SCHEDULE 13D/A Filing | 0001213900-25-039888 | View SEC Doc Filr Page |
| 20-F | 2025-04-30 | 2024-12-31 | ANNUAL REPORT | 0001213900-25-037199 | View SEC Doc Filr Page |
| 6-K | 2025-04-30 | 2025-04-30 | REPORT OF FOREIGN PRIVATE ISSUER | 0001213900-25-037097 | View SEC Doc Filr Page |
| S-8 | 2025-04-04 | — | REGISTRATION STATEMENT | 0001213900-25-029036 | View SEC Doc Filr Page |
| 6-K | 2025-03-10 | 2025-03-10 | REPORT OF FOREIGN PRIVATE ISSUER | 0001213900-25-022236 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2025-02-14 | — | SCHEDULE 13G/A Filing | 0001172661-25-001302 | View SEC Doc Filr Page |
| 6-K | 2024-12-20 | 2024-12-20 | REPORT OF FOREIGN PRIVATE ISSUER | 0001213900-24-110771 | View SEC Doc Filr Page |
| SC 13G | 2024-11-14 | — | SC 13G Filing | 0001172661-24-005081 | View SEC Doc Filr Page |
| 6-K | 2024-10-04 | 2024-10-04 | REPORT OF FOREIGN PRIVATE ISSUER | 0001213900-24-085537 | View SEC Doc Filr Page |
| 6-K | 2024-09-24 | 2024-06-30 | REPORT OF FOREIGN PRIVATE ISSUER | 0001213900-24-081199 | View SEC Doc Filr Page |
| 6-K | 2024-09-19 | 2024-09-19 | REPORT OF FOREIGN PRIVATE ISSUER | 0001213900-24-080300 | View SEC Doc Filr Page |
| 424B4 | 2024-09-18 | — | PROSPECTUS | 0001213900-24-079889 | View SEC Doc Filr Page |
| EFFECT | 2024-09-17 | — | EFFECT Filing | 9999999995-24-002863 | View SEC Doc Filr Page |
| CORRESP | 2024-09-16 | — | CORRESP Filing | 0001213900-24-078897 | View SEC Doc Filr Page |
| CORRESP | 2024-09-16 | — | CORRESP Filing | 0001213900-24-078894 | View SEC Doc Filr Page |
| F-1/A | 2024-09-16 | — | AMENDMENT NO. 2 TO FORM F-1 | 0001213900-24-078891 | View SEC Doc Filr Page |
| F-1/A | 2024-09-16 | — | AMENDMENT NO. 1 TO FORM F-1 | 0001213900-24-078764 | View SEC Doc Filr Page |
| UPLOAD | 2024-08-28 | — | UPLOAD Filing | 0000000000-24-009798 | View SEC Doc Filr Page |
| F-1 | 2024-08-22 | — | REGISTRATION STATEMENT | 0001213900-24-071896 | View SEC Doc Filr Page |